Investing in pre-seed and seed-stage startups with the potential to revolutionize healthcare. We invest in devices, diagnostics, manufacturing, and software.
@StephNass For founders in our niche (AI-native healthcare hardware), it's virtually always the slow path.
However, the potential grant sizes are a lot bigger. We have one portfolio company that has raised about $2M total while securing over $10M in grant funding!
@edwardlando Agree. We like to invest in capital-efficient founders for this reason. They can keep running the business until conventional wisdom catches up!
@edwardlando Future foundation models will rely on unique data generated through patent-protected hardware and workflows, especially in healthcare.
The fuel for next-gen models is propriatary data, not data centers.
@deedydas You implicitly assume startups that hit will deliver massive returns. But that hasn't always worked in bubble scenarios.
Look at Amazon. Investors at the height of the dotcom bubble didn't get back to break-even for over a decade even though they picked a huge winner.
@agupta Everyone is chasing the models, but clinical-grade modeling will require tons of clinical-grade data.
Tomorrow's models will be powered by the results of millions of microexperiments.
@Carles_Reina You might be right, but we are old enough to remember people saying exactly the same thing at the height of the dotcom bubble. But maybe this time will indeed be different.
@arian_ghashghai 100% agree. We invest in early-stage medical technology, a field that is experiencing its own AI revolution. But, because most investors are deterred by the long time horizons, we have plenty of great investment opportunities to choose from!
We do not expect care to be driven by AI insights alone.
This detection ecosystem will function as a powerful super-assistant, enabling the best doctors to care for more patients with greater precision.
This future is just around the corner!๐ฎ
#HealthTech #RemotePatientMonitoring #HealthcareBreakthroughs
These days, patients rarely learn about health problems until worrying symptoms arise. By that point, the optimal moment for intervention may be past.
As early-stage MedTech investors, we are witnessing a technology revolution that is about to bust this outdated paradigm:๐งต
Weโre moving toward seamless integration of home sensors (some even furniture-embedded!) alongside next-generation at-home testing platforms.
Sophisticated AI will synthesize this rich data stream into actionable insights.